71 – 80 of 102
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Histology-driven chemotherapy of soft-tissue sarcoma.
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2009
-
Mark
DEVELOPMENT OF IMMUNOHISTOCHEMICAL SURROGATES FOR PREDICTION OF BREAST CANCER PATIENT OUTCOME VIA HIGH-THROUGHPUT ANTIBODY GENERATION AND APPLICATION OF TISSUE MICROARRAY TECHNOLOGY: AN INITIAL REPORT
(
- Contribution to journal › Published meeting abstract
-
Mark
Empirically derived psychosocial states among adolescents diagnosed with cancer during the acute and extended phase of survival
(
- Contribution to journal › Article
-
Mark
Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden
(
- Contribution to journal › Article
-
Mark
IDENTIFICATION OF NOVEL SECRETED TUMOR STROMA-DERIVED STIMULATORS OF PROSTATE CANCER GROWTH
2009) 7th International Symposium on Targeted Anticancer Therapies In Annals of Oncology 20(Suppl 3). p.34-34(
- Contribution to journal › Published meeting abstract
-
Mark
Cancer risks in Crohn disease patients
2009) In Annals of oncology : official journal of the European Society for Medical Oncology 20(3). p.80-574(
- Contribution to journal › Article
- 2008
-
Mark
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
(
- Contribution to journal › Article
-
Mark
Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST)
(
- Contribution to journal › Article
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142(
- Contribution to journal › Published meeting abstract